linjc16/ctgov huggingface dataset:
Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients

Study Overview
=================
Brief Summary
-----------------
Using to method of Proteomics, for aims to conquer intractable disease, try to access variety experiment. Biomarker is necessary to develop new diagnosis method and target of treatment.

Detailed Description
-----------------
Following Seoul National University Hospital Institutional Review Board approval, obtain serum and platelet with neurodegeneration patients and control group visited the part of neurology, there'll be analysis to differentiate each other diseases use to method Proteomics. Biomarker will be screening via 1D/2D analysis, Mass analysis, database searching- the MASCOT search tool, SWISS-PROT and etc.

Official Title
-----------------
Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients

Conditions
-----------------
Biomarker With Neurodegeneration Patients

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: neurodegeneration patients and control group include dementia patients visited the part of neurology. over the age of 18 when participants can understand subject of this study Total point of Mini Mental state exam(MMSE)should be Under 26 include MCI (mild cognitive impairment) and over GDS score 3points. exclusion criteria: under eighteen years of age when participants cannot understand subject of this study cannot accept this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| neurodegeneration patients<br>•neurodegeneration patients and control group include dementia patients visited the part of neurology | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Ambulatory Surgery of Lower Extremity Varicose Vein

Study Overview
=================
Brief Summary
-----------------
OBJECTIVE: To retrospectively analyze the results of ambulatory treatment on Taiwanese patients with primary varicosities of the lower extremities including the use of endovenous laser, phlebectomy, and sclerotherapy. METHODS: We routinely used tumescent anesthesia and ultrasound-guided approaches for the application of endovenous laser. Vein access was achieved by either a percutaneous or stab wound. The laser power was usually 10 - 20 watts; laser treatment usually was begun from 4-10 cm below the saphenofemoral junction, and stopped around the knee, not over 10 cm below the knee. In the same operation, we used Mueller's phlebectomy and/or sclerotherapy if there were prominent branch varicosities. We instructed each patient to walk around immediately after the operation, to go home, and to come back 1-3 days later for follow-up. Ultrasound scan and venous function follow-up was scheduled at 1 month, 6 months, 12 months, and then annually.

Conditions
-----------------
Varicose Veins

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with varicose veins who underwent endovenous laser treatment for GSV reflux in our hospital were reviewed Exclusion Criteria: poor general health, inability to walk, active inflammation of varicose veins, deep venous occlusion disease, hypercoagulability, pregnancy and breast-feeding.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Development of an Urticaria Control Test

Study Overview
=================
Brief Summary
-----------------
The aim of the project is to develop a patient reported outcome instrument to assess disease control in chronic urticaria patients (Urticaria Control Test - UCT) of age 12 and older.

Official Title
-----------------
UCT - Development of an Instrument to Assess Disease Control in Patients With Chronic Urticaria (Urticaria Control Test)

Conditions
-----------------
Chronic Urticaria

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients suffering from chronic forms of urticaria are eligible

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| chronic urticaria patients<br>all patients suffering from chronic types of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
urticaria, patient reported outcome
Medicinal Plant Use for Treating Inflammation Among Dominicans in New York City and the Dominican Republic

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate and compare the use of herbal medicine among Dominicans in New York City and the Dominican Republic.

Detailed Description
-----------------
According to the 2000 U.S. Census Report, Dominicans constitute the largest Hispanic immigrant group in New York City. Studies have shown that immigrants' use of traditional and herbal medicine is close to that of native-born Americans. However, minority immigrants often have limited access to traditional health care; as a result, they may be more likely to consult with traditional healers and use medicinal plants than nonimmigrants. This study is designed to increase knowledge about immigrants' health and to contribute to more culturally-sensitive health care. The purpose of this study is to determine medical plant knowledge and use among Dominican traditional healers and patients in New York City and in the Dominican Republic. This study will comprise two parts. In Part I, Dominican medicinal plant users and Dominican traditional healers in New York City will be questioned about the medicinal plant species they know and how they are used for prevalent illnesses. The same number of participants will be interviewed in the Dominican Republic, allowing for detailed comparisons between the two study sites. In Part II, the most frequently-cited medicinal plant species will be subjected to a thorough literature review on their pharmacologic activity and the chemical composition of their active constituents. Two in vitro assays will be used to measure the anti-inflammatory activity of certain plant extracts, and their anti-inflammatory compounds will be isolated and characterized for the purpose of standardization of active extracts. On the basis of these results, recommendations will be formulated for future studies and community use of selected medicinal plant species.

Official Title
-----------------
Dominican Herbal Medicine: Plants Used for Inflammation

Conditions
-----------------
Inflammation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dominican ethnicity Have knowledge of Dominican medicinal plants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of culturally important medicinal plants |  | June 2010 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Complementary Therapies, Plants, Medicinal, Dominican Republic, Hispanic Americans
Hypertrophic Scarring After Facial Burn

Study Overview
=================
Brief Summary
-----------------
Subjects with a burn to the face and/or neck will be enrolled into the study and a Three-Dimensional scanner used to see if it can objectively measure scar color and volume and measure the effect of scar on motion of the face and neck.

Detailed Description
-----------------
Subjects will have 11 clinic visits over a 2-year period. An initial scan of the subject's head and neck will be made. Ten reproducible landmarks on the face and neck will be determined. The subject will return for follow up scans at Day 14, Day 28 and Month 2,6,9,12,18 and 24.

Official Title
-----------------
Hypertrophic Scarring After Facial Burn: A Pilot, Observational Study of Static and Dynamic Measurements of Facial Scars With the 3-D Scanner Through the Scar Maturation Process

Conditions
-----------------
Burn

Intervention / Treatment
-----------------
* Device: 3-Dimensional Color Scanning


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Face and/or Neck Burn

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: 3-Dimensional Color Scanning|Color imaging of the face and neck.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scar maturation | Can a 3-D scanner measure static and dynamic changes | 5.5 years |
A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381

Study Overview
=================
Brief Summary
-----------------
This 2 arm study will assess the long term safety and efficacy of RO4607381 in patients with coronary heart disease or a coronary heart disease (CHD) risk equivalent who have completed study NC19453. Patients eligible to participate in the extension study will continue on the treatment they were originally assigned to ie RO4607381 (900mg po) or placebo daily, with concomitant daily atorvastatin (10 to 80mg po). The anticipated time on study treatment is 6 months post study NC19453, and the target sample size is approximately 100 individuals.

Official Title
-----------------
A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381

Conditions
-----------------
Coronary Heart Disease

Intervention / Treatment
-----------------
* Drug: dalcetrapib (RO4607381)
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who have completed treatment on study NC19453. Exclusion Criteria: any significant lymph node abnormalities at the end of study NC19453.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: dalcetrapib (RO4607381)<br> | Drug: dalcetrapib (RO4607381)<br>* 900mg po daily for 24 weeks<br>|
| Placebo Comparator: placebo<br> | Drug: placebo<br>* po daily for 24 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent Change From Baseline in HDL-C |  | Baseline and Week 24 (Week 48 from start of NC19453(NCT00353522)) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), Low Density Lipoprotein Cholesterol (LDL-C), Triglycerides (TG), Apolipoprotein B (ApoB) and Apolipoprotein A1 (ApoA1) |  | Baseline and Week 24 (Week 48 from start of NC19453) |
Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity

Study Overview
=================
Brief Summary
-----------------
To evaluate the possibility that erythropoietin with early iron supplementation may induce retinopathy of prematurity or worsen this disease. In addition risk factors for the development of ROP will be checked.

Official Title
-----------------
The Possible Influence of Erythropoietin and Early Iron Supplements on the Prevalence and Severity of Retinopathy of Prematurity and Other Short Term Outcome of Prematurity

Conditions
-----------------
Retinopathy of Prematurity

Intervention / Treatment
-----------------
* Drug: erythropoietin and early iron supplements


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all premature infants with birth weight of 1250 grams or less Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 2 Weeks
Maximum Age: 3 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: erythropoietin and early iron supplements|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Iron, Erythropoietin, Retinopathy of prematurity
Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma

Study Overview
=================
Brief Summary
-----------------
To determine safety profile of immunotherapy with natural killer cells and activated expanded (NKAEs) after salvage chemotherapy in relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma.

Official Title
-----------------
Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma.

Conditions
-----------------
Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma

Intervention / Treatment
-----------------
* Biological: Expanded haploidentical natural killer cells (NKAEs)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged between 0 and 21 years with relapsed or refractary acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Lansky Index > 60%. Left ventricular ejection fraction > 39%. Negative HIV serology. Provide informed consent in accordance with current legislation. Exclusion Criteria: Patients with a history of poor compliance. Patients not valid after psycho-social evaluation Severe (4) functional organ disorders (hepatic, renal, respiratory) according to NCI CTCAE v3 criteria

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Activated natural killer cells<br>Activated natural killer cells | Biological: Expanded haploidentical natural killer cells (NKAEs)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety profile (number of AEs per patient) |  | Two months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of episodes of febrile neutropenia, bacteriemia or viral or fungal infections |  | During 14 months | 
| time to hematological recovery (days) | hematological recovery: neutrophils >500/mm3, lymphocytes >250/mm3 and platelets >50.000/mm3) | 2 months | 
| days of hospitalization in each cycle |  | 2 months | 
| Objective response rate | Objective response rate according to cytomorphic and by minimal residual disease criteria (cytometry and/or real time PCR) | 2 months | 
| days of isolation |  | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immunotherapy, NKAEs, Expanded haploidentical natural killer cells, Activated natural killer cells
Effects of Hyperthyroidism on Amount and Activity of Brown Adipose Tissue

Study Overview
=================
Brief Summary
-----------------
The investigators wish to evaluate the effect of thyroid hormones on brown adipose tissue in humans in an observational study on patients with thyrotoxicosis. In the investigators evaluation the investigators will use FDG-PET/CT, indirect calorimetry and fat biopsies in the acute phase of the disease and in the euthyroid phase after treatment. It is the investigators hypothesis that high levels of circulating T3 might affect amount and function of brown adipose tissue.

Detailed Description
-----------------
10 patients with thyreotoxicosis (T3 > 3 nmol/L and suppressed TSH) will be investigated at diagnosis and after 3-6 months of euthyroidism induced by antithyroid treatment. The patients will all be over the age of 50 due to the radiation given by the scans (requested by the local Ethical Committee). All will be scanned for active BAT by the integrated FDG PET-CT before and after treatment.BAT is activated by means of crushed ice placed under the feet in individualized intervals during the scan procedure. Indirect calorimetry is done to determine the basal metabolic rate and subcutaneous fat biopsy to examine the effect on subcutaneous white fat and the possible browning effect.

Official Title
-----------------
Identification and Regulation of Brown Adipose Tissue (BAT) in Humans. Implications for Energy Expenditure in Humans and in the Treatment of Obesity and Related Metabolic Diseases

Conditions
-----------------
Hyperthyroidism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: men and women with hyperthyroidism (T3 > 3 nmol/l) > 50 years old women must be postmenopausal Exclusion Criteria: thyrotoxic crises severe concurrent sickness that will make it unsafe to postpone treatment, this includes severe kidney disease (creatinin over 160)- and heart disease (NYHA group 3 and 4). diabetes former and current treatment with interleukin-2 Patients who are already treated with β-blockers severe claustrophobia BMI > 30 kg/m2

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| T3 > 4 nmol/l<br>Acute hyperthyroidism with a T3 > 4 nmol/l | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FDG-PET/CT-scanning | Changes in Brown adipose tissue FDG uptake | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Indirect Calorimetry | Changes in basal energy expenditure | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brown Adipose Tissue
A Prospective Trial of the Intelon BOSS(TM) System

Study Overview
=================
Brief Summary
-----------------
A prospective, open-label, single-site clinical trial designed to evaluate the repeatability and reproducibility of biomechanical imaging by the BOSS device. Subjects will undergo unilateral biomechanical mapping of the cornea and lens by three BOSS devices operated by three (3) different operators.

Official Title
-----------------
A Prospective Trial Designed to Evaluate the Repeatability and Reproducibility of the Intelon BOSS(TM) System

Conditions
-----------------
Cornea, Lens Diseases

Intervention / Treatment
-----------------
* Other: Brillouin Spectroscopy via BOSS System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older Availability, willingness and sufficient cognitive awareness to comply with the examination procedures and schedule Signed Written Informed Consent Exclusion Criteria: No light perception or low vision rendering the subject unable to fixate to keep gaze still enough to acquire images Presence of corneal opacity Presence of cortical cataracts visible in an undilated pupil Any systemic disease or disorder which would prohibit image acquisition (e.g., Parkinson's Disease).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Imaging by BOSS System<br>Imaging by the BOSS System | Other: Brillouin Spectroscopy via BOSS System<br>* Biomechanical Imaging of the Cornea and Lens<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of variance in corneal and lens measurements to determine repeatability and reproducibility | A random effect model will be used to assess variation due to device/operator configuration | Evaluation Visit (within 30 days of the Screening Visit) |